The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $131.79

Today's change+1.98 +1.53%
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $131.79

Today's change+1.98 +1.53%
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc Hits New 50-day High

Alexion Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$1.98 or 1.53% to (U.S.)$131.79 and setting a new 50-day high. Over the last five days, shares have gained 4.01% and 7.72% year to date. Shares have underperformed the S&P 500 by 10.67% during the last year.

Key company metrics

  • Open(U.S.) $129.42
  • Previous close(U.S.) $129.81
  • High(U.S.) $132.01
  • Low(U.S.) $129.01
  • Bid / Ask(U.S.) $123.00 / (U.S.) $132.50
  • YTD % change+7.72%
  • Volume1,910,793
  • Average volume (10-day)1,447,712
  • Average volume (1-month)2,763,866
  • Average volume (3-month)2,726,224
  • 52-week range(U.S.) $96.18 to (U.S.) $145.42
  • Beta1.42
  • Trailing P/E62.58×
  • P/E 1 year forward24.39×
  • Forward PEG1.35×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.11
Updated July 21 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.53%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue870831799753
Total other revenue--------
Total revenue870831799753
Gross profit801763728692
Total cost of revenue69677161
Total operating expense658704620558
Selling / general / administrative262260230232
Research & development219206196179
Depreciation / amortization80808280
Interest expense (income), net operating--------
Unusual expense (income)2891417
Other operating expenses, total--------
Operating income212127179195
Interest income (expense), net non-operating-24-25----
Gain (loss) on sale of assets--------
Other--------
Income before tax194104158170
Income after tax1709294115
Income tax, total24126455
Net income1709294115
Total adjustments to net income--------
Net income before extra. items1709294115
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1709294115
Inc. avail. to common incl. extra. items1709294115
Diluted net income1709294115
Dilution adjustment--------
Diluted weighted average shares226228226226
Diluted EPS excluding extraordinary itemsvalue per share0.750.400.420.51
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share0.860.760.530.53